BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Merck KGaA

Open

121.4 1.42

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

119.7

Max

122.55

Belangrijke statistieken

By Trading Economics

Inkomsten

-142M

667M

Verkoop

152M

5.4B

K/W

Sectorgemiddelde

26.27

57.333

EPS

2.2

Dividendrendement

1.34

Winstmarge

12.311

EBITDA

85M

1.6B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+38.83% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.34%

2.63%

Volgende Winsten

15 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

33B

98B

Vorige openingsprijs

119.98

Vorige sluitingsprijs

121.4

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Merck KGaA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 mrt 2025, 06:27 UTC

Winsten

Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results

11 feb 2025, 07:03 UTC

Acquisities, Fusies, Overnames

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10 feb 2025, 16:38 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

24 apr 2025, 22:51 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into

24 apr 2025, 20:50 UTC

Acquisities, Fusies, Overnames

Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share

24 apr 2025, 19:05 UTC

Acquisities, Fusies, Overnames

Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ

24 apr 2025, 19:05 UTC

Acquisities, Fusies, Overnames

Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ

24 apr 2025, 19:05 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ

24 apr 2025, 19:05 UTC

Acquisities, Fusies, Overnames

Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ

6 mrt 2025, 11:18 UTC

Marktinformatie
Winsten

Impact from U.S. Tariffs Is Manageable for Merck KGaA, CEO Says -- Market Talk

6 mrt 2025, 11:14 UTC

Marktinformatie

Merck KGaA's Outlook Signals Greater Transparency -- Market Talk

6 mrt 2025, 08:20 UTC

Marktinformatie
Winsten

Merck KGaA's Earnings Guidance Seems Soft Amid Semiconductor Uncertainty -- Market Talk

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA Expects 2025 Net Sales Between EUR21.5B and EUR22.9B

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 Adj EPS EUR8.63

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA Expects 2025 EBITDA Before One-Time Items Between EUR6.1B and EUR6.6B

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 EBIT EUR3.645B

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 After-Tax Profit EUR2.79B

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 Ebitda Before One-Time Items EUR6.07B

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 EBITDA EUR5.78B

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA 2024 Sales EUR21.16B

6 mrt 2025, 06:00 UTC

Winsten

Merck KGaA Keeps Dividend at EUR2.20

6 mrt 2025, 06:00 UTC

Winsten

Analysts Saw Merck KGaA 2024 Sales at EUR21.14B

6 mrt 2025, 06:00 UTC

Winsten

Analysts Saw Merck KGaA 2024 Ebitda Before One-Time Items at EUR6.08B

11 feb 2025, 16:45 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk

11 feb 2025, 10:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11 feb 2025, 10:52 UTC

Marktinformatie
Acquisities, Fusies, Overnames

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

6 jan 2025, 13:08 UTC

Acquisities, Fusies, Overnames

Merck KGaA: Transaction closed on Dec. 23, 2024

6 jan 2025, 13:07 UTC

Acquisities, Fusies, Overnames

Merck KGaA: Didn't Disclose Financial Details

6 jan 2025, 13:06 UTC

Acquisities, Fusies, Overnames

Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio

Peer Vergelijking

Prijswijziging

Merck KGaA Prognose

Koersdoel

By TipRanks

38.83% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 166.25 EUR  38.83%

Hoogste 190 EUR

Laagste 107 EUR

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck KGaA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

6

Buy

2

Hold

1

Sell

Technische score

By Trading Central

117.55 / 120.4Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merck KGaA

There is no Profile data available for MRK.BE.